Search research articles
Contact Us
Filters
Showing results (21-30 of 39) with videos related to
Page
of 4
Sort By:
Journal of the American Society of Nephrology : JASN
|
April 10, 2009
Agalsidase alfa and kidney dysfunction in Fabry disease
Michael West, Kathy Nicholls, Atul Mehta, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 8, 2014
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study
Richard Furie, Kathy Nicholls, Tien-Tsai Cheng, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 27, 2010
Therapeutic goals in the treatment of Fabry disease
Atul Mehta, Michael L West, Guillem Pintos-Morell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 22, 2010
Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature
Olivier Lidove, Michael L West, Guillem Pintos-Morell, et al.
Orphanet Journal of Rare Diseases
|
March 29, 2025
Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys
Shoshana Revel-Vilk, Uma Ramaswami, Guillem Pintos-Morell, et al.
Journal of the American College of Cardiology
|
February 26, 2011
Cardiovascular events in patients with fabry disease natural history data from the fabry registry
Manesh R Patel, Franco Cecchi, Marta Cizmarik, et al.
Journal of the American College of Cardiology
|
March 21, 2006
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial
Sophia Zoungas, Barry P McGrath, Pauline Branley, et al.
Orphanet Journal of Rare Diseases
|
November 27, 2012
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
Dominique P Germain, Roberto Giugliani, Derralynn A Hughes, et al.
Orphanet Journal of Rare Diseases
|
October 21, 2023
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
Aleš Linhart, Gabriela Dostálová, Kathy Nicholls, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
May 18, 2013
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa
Raphael Schiffmann, Markus Ries, Derek Blankenship, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 39) with videos related to
Sort By:
Page
of 4
Journal of the American Society of Nephrology : JASN
|
April 10, 2009
Agalsidase alfa and kidney dysfunction in Fabry disease
Michael West, Kathy Nicholls, Atul Mehta, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 8, 2014
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study
Richard Furie, Kathy Nicholls, Tien-Tsai Cheng, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 27, 2010
Therapeutic goals in the treatment of Fabry disease
Atul Mehta, Michael L West, Guillem Pintos-Morell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 22, 2010
Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature
Olivier Lidove, Michael L West, Guillem Pintos-Morell, et al.
Orphanet Journal of Rare Diseases
|
March 29, 2025
Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys
Shoshana Revel-Vilk, Uma Ramaswami, Guillem Pintos-Morell, et al.
Journal of the American College of Cardiology
|
February 26, 2011
Cardiovascular events in patients with fabry disease natural history data from the fabry registry
Manesh R Patel, Franco Cecchi, Marta Cizmarik, et al.
Journal of the American College of Cardiology
|
March 21, 2006
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial
Sophia Zoungas, Barry P McGrath, Pauline Branley, et al.
Orphanet Journal of Rare Diseases
|
November 27, 2012
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
Dominique P Germain, Roberto Giugliani, Derralynn A Hughes, et al.
Orphanet Journal of Rare Diseases
|
October 21, 2023
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
Aleš Linhart, Gabriela Dostálová, Kathy Nicholls, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
May 18, 2013
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa
Raphael Schiffmann, Markus Ries, Derek Blankenship, et al.
Page
of 4